Industry P pharmaphorum
The hidden pandemic within the pandemic: How COVID-19 impacted sepsis – and what comes next
The hidden pandemic within the pandemic: How COVID-19 impacted sepsis – and what comes next Nicole.Raleigh Mon, 05/10/2026 - 09:30
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry P pharmaphorum
The hidden pandemic within the pandemic: How COVID-19 impacted sepsis – and what comes next Nicole.Raleigh Mon, 05/10/2026 - 09:30
Industry
MedTech Dive
Thermo Fisher turned fragmented KOL data into real-time market demand. Read how.
Industry
BioPharma Dive
Why diagnostic-driven therapies need a new commercialization model to reach more eligible patients.
Industry P pharmaphorum
CSL joins forces with Alentis on claudin candidate Phil.Taylor Mon, 05/10/2026 - 08:54
Industry
STAT Biotech
Peptides gained legitimacy at the FDA after being embraced by MAHA. Advocates hope stem cell treatments will follow the same path.
Industry
European Biotechnology
Australian biopharma company CSL has entered an exclusive global partnership with Basel-based Alentis Therapeutics to co-develop and co-commercialize lixudebart, an investigational antibody targeting claudin-1. CSL will pay Alentis $355 million upfront and the Swiss biotech is el…
Industry
Bio.News
Research Triangle Park resurgent with billions in investment in biotechnology manufacturing. With a famous biotech cluster in Research Triangle Park (RTP) established almost 70 […] The post BIO on the American Road visits pioneering NC biotech hub appeared first on Bio.News.
Industry B BioTechniques
Original story from Hefei Institutes of Physical Science, Chinese Academy of Sciences (Hefei, China). A magnet-producing bacterium extended the average lifespan of C. elegans worms by 43% by suppressing aging-related ferroptosis. Researchers at the Hefei Institutes of Physical Sc…
Industry
European Biotechnology
Justyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization readiness. The post Designing biologics for commercial success appeared first on Eur…
Industry N Nature Biomedical Engineering
Industry N Nature Biomedical Engineering
Industry N Nature Biomedical Engineering
Industry
Nature Biotechnology
Industry
Nature Reviews Drug Discovery
Industry N Nature Medicine
Industry N Nature Reviews Bioengineering
Industry
MedCity News
While the immune reset field is mainly focused on depleting pathogenic B cells, ai3Bio is applying its novel approach to inflammatory T cells. The startup’s initial disease targets are autoimmune disorders of the liver that have few treatment options if any at all. The post Immun…
Industry P Pharmafile
Brenntag Pharma and dsm-firmenich have entered a long-term global distribution partnership covering GMP-grade vitamins for biopharmaceutical manufacturing. Under the agreement, Brenntag will have exclusive distribution rights across North America, Latin America, Europe, the Middl…
Industry
BioCentury
BIOCENTURY | DEALSNOVARTIS TURNS TO MRNA-ENCODED ENGAGERS FOR B CELL DEPLETIONPharma pays $575M up front for Abogen’s CD3 x CD19 engager to treat autoimmune diseases
Industry
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTCIRCLE’S $92.5M ROUND PUTS CYCLIN D1 PROGRAM AHEAD OF CLINICAL LEADPreclinical combination data drive CID-165’s priority over CID-078, with deeper breast cancer responses the goal
Industry
BioCentury
BIOCENTURY | EDITOR'S COMMENTARYSMALL GLOBE, BIG PRECEDENT: A PERSPECTIVEThe mandatory Medicare Part B MFN model has shrunk, laying bare the real issues
Industry
BioCentury
BIOCENTURY | DATA BYTEPHARMA PARTNERING IN CHINA GETS EARLIER AND BROADERMerck, Novo and Novartis pay ≥$300M apiece for early assets as China partnering expands beyond cancer antibodies
Industry B BioPharm International
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
Industry
GEN
A long-duration single-molecule imaging platform from the Broad Institute and MIT has revealed unexpected stability in homodimers of HER3, one of the most enigmatic members of the ErbB receptor family. The post Watching Cancer Proteins in Real Time, with Help from Rare Earth Elem…
Industry
BioCentury
BIOCENTURY | FINANCEHATTERAS BANKS ON PORTFOLIO WITH UPSIZED OPPORTUNITY FUNDFirm sets $100M target for vehicle designed for further investment in private portfolio companies, even amid improved environment for exits
Industry
Fierce Biotech
Accelerating Oligonucleotide Therapeutics Oligonucleotide therapeutics represent a paradigm shift in precision medicine, targeting RNA to modulate gene expression with unmatched specificity for genetic and rare diseases. This eBook explores Evotec's oligonucleotide journey and cu…
Industry P Pharmaceutical Executive
Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral…
Industry
GEN
Working with mice, scientists have for the first time identified a set of neurons in the brain that play a role in generating anxiety after exposure to cannabinoid drugs, especially under stressful conditions. The post Neurons Involved in Generating Anxiety After Cannabinoid Drug…
Industry
Inside Precision Medicine
A new molecular diagnostic platform could help laboratories identify bacterial infections and key antimicrobial resistance genes more quickly and without specialized equipment. The post CRISPR-Based Test Offers Fast Antimicrobial Resistance Detection in Low-Resource Settings appe…
Industry
Inside Precision Medicine
A urine cell-free RNA test detected localized bladder cancer with high sensitivity and may also reveal residual disease and help predict response to BCG immunotherapy versus chemotherapy. The post Urine RNA Test Could Detect Bladder Cancer and Predict Treatment Response appeared…
Industry
Inside Precision Medicine
A blood-based epigenomic approach captured molecular features of small-cell lung cancer that are normally measured in tumor tissue. The method could eventually help clinicians monitor tumor state and subtype as disease evolves. The post Plasma Epigenomic Profiling May Enable Noni…
Industry
Fierce Pharma
Evaluating Combinatorial Targets for Precision Therapeutics: A Pathologist’s View scox Fri, 10/02/2026 - 13:10 Wed, 11/18/2026 - 12:00 Resource Type Webinar William Mifsud, PhD Tad George, PhD Promotion End Thu, 04/08/2027 - 13:14 Precision therapeutic strategies that target mult…
Industry B BioPharm International
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Industry
Pharmaceutical Processing World
ISO 9001, ISO 14001 and ISO 45001 are all being revised, which leaves quality (QMS), environmental (EMS) and occupational health and safety (OH&S) managers, along with top management, with required work ahead to meet the new requirements. Because the revisions put more weight…
Industry
European Biotechnology
Novartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an experimental treatment that uses mRNA to make a B-cell-depleting drug inside the patient’s body. The post Novartis bets up to $7.8B on Abogen’s mRNA autoimmune thera…
Industry B BioPharm International
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid art…
Industry B BioPharm International
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on…
Industry
BioPharma Dive
The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
Industry
LifeSciVC
By Julia Pian, Senior Associate at Atlas Venture, as part of the From The Trenches feature of LifeSciVC If you are an avid consumer of biopharma news, you are probably all too familiar with the graphs that plot the growth The post Chinese Biopharma: The Next Five Years appeared f…
Industry B BioPharm International
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.